These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 2362193)
1. In vivo fate of monoclonal antibody B72.3. Halpern SE J Nucl Med; 1990 Jul; 31(7):1143-6. PubMed ID: 2362193 [No Abstract] [Full Text] [Related]
2. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192 [TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233 [TBL] [Abstract][Full Text] [Related]
4. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989 [TBL] [Abstract][Full Text] [Related]
6. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317 [TBL] [Abstract][Full Text] [Related]
7. Tumor targeting with monoclonal antibody B72.3. Schlom J; Colcher D; Roselli M; Carrasquillo JA; Reynolds JC; Larson SM; Sugarbaker P; Tuttle SE; Martin EW Int J Rad Appl Instrum B; 1989; 16(2):137-42. PubMed ID: 2654088 [No Abstract] [Full Text] [Related]
8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011 [TBL] [Abstract][Full Text] [Related]
10. Imaging of colorectal carcinoma with 131I B72.3 monoclonal antibody. Carrasquillo JA Targeted Diagn Ther; 1992; 6():45-55. PubMed ID: 1576349 [No Abstract] [Full Text] [Related]
11. The in vivo binding behaviour of an I-123 labelled anti-granulocytes antibody (Granuloszint). Hasler PH; Novak-Hofer I; Bläuenstein P; Schubiger PA Prog Clin Biol Res; 1990; 355():299-309. PubMed ID: 2281110 [No Abstract] [Full Text] [Related]
12. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1. Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816 [TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Muraro R; Kuroki M; Wunderlich D; Poole DJ; Colcher D; Thor A; Greiner JW; Simpson JF; Molinolo A; Noguchi P Cancer Res; 1988 Aug; 48(16):4588-96. PubMed ID: 3396010 [TBL] [Abstract][Full Text] [Related]
14. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture. Johnston WW Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the colorectal antigen IOR C2.II. Vázquez AM; Tormo B; Velandia A; Gómez CA; Alfonso M; Giscombe R; Ansotegui I; Jeddi-Tehrani M; Pérez R; Mellstedt H Year Immunol; 1993; 7():137-45. PubMed ID: 7690506 [No Abstract] [Full Text] [Related]
16. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259 [TBL] [Abstract][Full Text] [Related]
17. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Meredith RF; Khazaeli MB; Grizzle WE; Orr RA; Plott G; Urist MM; Liu T; Russell CD; Wheeler RH; Schlom J Hum Antibodies Hybridomas; 1993 Oct; 4(4):190-7. PubMed ID: 8257773 [TBL] [Abstract][Full Text] [Related]
18. Oncologic theranostics: recognition of this concept in antigen-directed cancer therapy for colorectal cancer with anti-TAG-72 monoclonal antibodies. Povoski SP; Hatzaras IS; Mojzisik CM; Martin EW Expert Rev Mol Diagn; 2011 Sep; 11(7):667-70. PubMed ID: 21902525 [No Abstract] [Full Text] [Related]
19. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Fang L; Sun D Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268 [TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Pavlinkova G; Booth BJ; Batra SK; Colcher D Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]